PRKDC and prostate carcinoma: Pharmacologic inhibition of DNA-dependent protein kinase catalytic (DNA-PKc), a component of Non-homologous end joining (NHEJ) repair machinery, with all three inhibitors, significantly resensitized DU145-DxR (prostate cancer cell line model of docetaxel-resistance) to taxane (61).The efficacy of M3814 which is a DNA-PKc inhibition, is validating in NCT04071236.